- Home
- FGB vs KRON Comparison
FGB vs KRON Comparison
Compare FGB & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- KRON
- Stock Information
- Founded
- FGB 2007
- KRON 2017
- Country
- FGB United States
- KRON United States
- Employees
- FGB N/A
- KRON N/A
- Industry
- FGB Finance/Investors Services
- KRON Medicinal Chemicals and Botanical Products
- Sector
- FGB Finance
- KRON Health Care
- Exchange
- FGB Nasdaq
- KRON Nasdaq
- Market Cap
- FGB 61.1M
- KRON 60.3M
- IPO Year
- FGB N/A
- KRON 2020
- Fundamental
- Price
- FGB $4.22
- KRON $0.90
- Analyst Decision
- FGB
- KRON Buy
- Analyst Count
- FGB 0
- KRON 3
- Target Price
- FGB N/A
- KRON $1.63
- AVG Volume (30 Days)
- FGB 53.0K
- KRON 184.6K
- Earning Date
- FGB 01-01-0001
- KRON 11-13-2024
- Dividend Yield
- FGB 8.92%
- KRON N/A
- EPS Growth
- FGB N/A
- KRON N/A
- EPS
- FGB N/A
- KRON N/A
- Revenue
- FGB N/A
- KRON $9,864,000.00
- Revenue This Year
- FGB N/A
- KRON $52.58
- Revenue Next Year
- FGB N/A
- KRON N/A
- P/E Ratio
- FGB N/A
- KRON N/A
- Revenue Growth
- FGB N/A
- KRON 146.56
- 52 Week Low
- FGB $2.85
- KRON $0.69
- 52 Week High
- FGB $3.74
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- FGB 67.50
- KRON 49.20
- Support Level
- FGB $4.14
- KRON $0.84
- Resistance Level
- FGB $4.21
- KRON $0.88
- Average True Range (ATR)
- FGB 0.05
- KRON 0.05
- MACD
- FGB 0.01
- KRON 0.00
- Stochastic Oscillator
- FGB 76.00
- KRON 57.22
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.